

William J Taylor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/514750/publications.pdf>

Version: 2024-02-01

157
papers

10,358
citations

87888

38
h-index

34986

98
g-index

161
all docs

161
docs citations

161
times ranked

8428
citing authors

#	ARTICLE	IF	CITATIONS
1	Gout Flare Severity From the Patient Perspective: A Qualitative Interview Study. Arthritis Care and Research, 2022, 74, 317-323.	3.4	12
2	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	3.4	23
3	The GOUT-36 prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation. Rheumatology, 2022, 61, 1658-1662.	1.9	4
4	Which Attributes Are Most and Least Important to Patients When Considering Gout Flare Burden Over Time? A Best-worst Scaling Choice Study. Journal of Rheumatology, 2022, 49, 213-218.	2.0	1
5	Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatology, The, 2022, 4, e53-e60.	3.9	18
6	Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nationwide population-based cohort study. International Journal of Rheumatic Diseases, 2022, 25, 154-162.	1.9	2
7	Stakeholder perspectives of the sociotechnical requirements of a telehealth wheelchair assessment service in Aotearoa/New Zealand: A qualitative analysis. Australian Occupational Therapy Journal, 2022, 69, 279-289.	1.1	3
8	Is repeat serum urate testing superior to a single test to predict incident gout over time?. PLoS ONE, 2022, 17, e0263175.	2.5	0
9	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. Journal of Rheumatology, 2021, 48, 293-298.	2.0	11
10	Which factors predict discordance between a patient and physician on a gout flare?. Rheumatology, 2021, 60, 773-779.	1.9	5
11	Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey. Journal of Rheumatology, 2021, 48, 152-153.	2.0	5
12	Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nature Reviews Rheumatology, 2021, 17, 109-118.	8.0	73
13	What is remission in gout and how should we measure it?. Rheumatology, 2021, 60, 1007-1009.	1.9	4
14	The effect of the Take Charge intervention on mood, motivation, activation and risk factor management: Analysis of secondary data from the Taking Charge after Stroke (TaCAS) trial. Clinical Rehabilitation, 2021, 35, 1021-1031.	2.2	10
15	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. BMC Rheumatology, 2021, 5, 33.	1.6	0
16	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 946-950.	3.4	11
17	What Represents Treatment Efficacy in Long-term Studies of Gout Flare Prevention? An Interview Study of People With Gout. Journal of Rheumatology, 2021, 48, jrheum.210476.	2.0	1
18	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 1378-1385.	3.4	3

#	ARTICLE	IF	CITATIONS
19	Care of patients with early inflammatory arthritis in the Wellington region according to the British Society of Rheumatology's best practice tariff standards. <i>New Zealand Medical Journal</i> , 2021, 134, 71-79.	0.5	0
20	Evaluating the effectiveness of therapeutic horse riding for children and young people experiencing disability: a single-case experimental design study. <i>Disability and Rehabilitation</i> , 2020, 42, 3734-3743.	1.8	6
21	Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network. <i>Internal Medicine Journal</i> , 2020, 50, 17-23.	0.8	8
22	Exploring how therapeutic horse riding improves health outcomes using a realist framework. <i>British Journal of Occupational Therapy</i> , 2020, 83, 129-139.	0.9	9
23	How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 303-313.	3.4	16
24	Development of a prediction model for inpatient gout flares in people with comorbid gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 418-423.	0.9	18
25	Outcome Measures in Gout. <i>Arthritis Care and Research</i> , 2020, 72, 72-81.	3.4	1
26	The impact of gout as described by patients, using the lens of The International Classification of Functioning, Disability and Health (ICF): a qualitative study. <i>BMC Rheumatology</i> , 2020, 4, 50.	1.6	4
27	Codevelopment of Patient Self-Examination Methods and Joint Count Reporting for Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 705-709.	2.1	4
28	Patient and clinician views on an app for rheumatoid arthritis disease monitoring: Function, implementation and implications. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 813-827.	1.9	20
29	The experience of a gout flare: a meta-synthesis of qualitative studies. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 805-811.	3.4	28
30	Taking Charge after Stroke: A randomized controlled trial of a person-centered, self-directed rehabilitation intervention. <i>International Journal of Stroke</i> , 2020, 15, 954-964.	5.9	43
31	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
32	The challenges of gout flare reporting: mapping flares during a randomized controlled trial. <i>BMC Rheumatology</i> , 2019, 3, 27.	1.6	13
33	Use of multi-attribute decision-making to inform prioritization of Cochrane review topics relevant to rehabilitation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 55, 322-330.	2.2	3
34	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
35	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. <i>PLoS ONE</i> , 2019, 14, e0226906.	2.5	1
36	Response to: "The reference levels of serum urate for clinically evident incident gout" by Chen and Ding. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e42-e42.	0.9	0

#	ARTICLE	IF	CITATIONS
37	A survey of the New Zealand rheumatology workforce. New Zealand Medical Journal, 2019, 132, 70-76.	0.5	5
38	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
39	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
40	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
41	Important features of retail shoes for women with rheumatoid arthritis: A Delphi consensus survey. , 2019, 14, e0226906.		0
42	Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Annals of the Rheumatic Diseases, 2018, 77, 1048-1052.	0.9	131
43	Predictors of activity limitation in people with gout: a prospective study. Clinical Rheumatology, 2018, 37, 2213-2219.	2.2	7
44	The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. Seminars in Arthritis and Rheumatism, 2018, 48, 456-461.	3.4	5
45	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. Journal of Rheumatology, 2018, 45, 419-424.	2.0	15
46	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Seminars in Arthritis and Rheumatism, 2018, 48, 293-301.	3.4	32
47	Allopurinol and peripheral vascular disease: enough observational data to warrant interventional studies. Rheumatology, 2018, 57, 408-409.	1.9	1
48	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis and Rheumatology, 2018, 70, 462-467.	5.6	68
49	The patient experience of musculoskeletal imaging tests for investigation of inflammatory arthritis: a mixed-methods study. Clinical Rheumatology, 2018, 37, 2261-2268.	2.2	4
50	Scoping review of priority setting of research topics for musculoskeletal conditions. BMJ Open, 2018, 8, e023962.	1.9	28
51	Rasch analysis suggests that health assessment questionnaire II is a generic measure of physical functioning for rheumatic diseases: a cross-sectional study. Health and Quality of Life Outcomes, 2018, 16, 108.	2.4	4
52	Physicianâ€™s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. Journal of Rheumatology, 2018, 45, 1256-1262.	2.0	10
53	Performance of the 2015 ACR-EULAR classification criteria for gout in a primary care population presenting with monoarthritis. Rheumatology, 2017, 56, 1335-1341.	1.9	12
54	Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study. Journal of Rheumatology, 2017, 44, 368-373.	2.0	28

#	ARTICLE	IF	CITATIONS
55	Crystal identification of synovial fluid aspiration by polarized light microscopy. An online test suggesting that our traditional rheumatologic competence needs renewed attention and training. <i>Clinical Rheumatology</i> , 2017, 36, 641-647.	2.2	41
56	Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard. <i>Arthritis and Rheumatology</i> , 2017, 69, 429-438.	5.6	93
57	Illness Perceptions and Mortality in Patients With Gout: A Prospective Observational Study. <i>Arthritis Care and Research</i> , 2017, 69, 1444-1448.	3.4	16
58	What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions. <i>Patient</i> , 2017, 10, 65-79.	2.7	38
59	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1870-1882.	0.9	98
60	Apps for People With Rheumatoid Arthritis to Monitor Their Disease Activity: A Review of Apps for Best Practice and Quality. <i>JMIR MHealth and UHealth</i> , 2017, 5, e7.	3.7	127
61	Patient-Clinician Co-Design Co-Participation in Design of an App for Rheumatoid Arthritis Management via Telehealth Yields an App with High Usability and Acceptance. <i>Studies in Health Technology and Informatics</i> , 2017, 245, 1223.	0.3	3
62	Performance of classification criteria for gout in early and established disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 178-182.	0.9	36
63	Pros and cons of conjoint analysis of discrete choice experiments to define classification and response criteria in rheumatology. <i>Current Opinion in Rheumatology</i> , 2016, 28, 117-121.	4.3	9
64	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48
65	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. <i>Arthritis Care and Research</i> , 2016, 68, 1894-1898.	3.4	34
66	Factors associated with change in radiographic damage scores in gout: a prospective observational study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2075-2079.	0.9	13
67	Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. <i>Rheumatology</i> , 2016, 55, 1771-1776.	1.9	25
68	Development and First Validation of a Disease Activity Score for Gout. <i>Arthritis Care and Research</i> , 2016, 68, 1530-1537.	3.4	24
69	Discrepancies in how the impact of gout is assessed in outcomes research compared to how health professionals view the impact of gout, using the lens of the International Classification of Functioning, Health and Disability (ICF). <i>Clinical Rheumatology</i> , 2016, 35, 2259-2268.	2.2	5
70	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. <i>BMJ Open</i> , 2016, 6, e012026.	1.9	5
71	Gout Classification Criteria: Update and Implications. <i>Current Rheumatology Reports</i> , 2016, 18, 46.	4.7	8
72	What Should Be the Cut Point for Classification Criteria of Studies in Gout? A Conjoint Analysis. <i>Arthritis Care and Research</i> , 2016, 68, 1731-1735.	3.4	4

#	ARTICLE	IF	CITATIONS
73	Editorial: Shifting the Goal Posts: Treatment Recommendations for Ankylosing Spondylitis and the Newly Defined Condition of Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 265-269.	5.6	5
74	Classification Criteria for Psoriasis and Psoriatic Arthritis. , 2016, , 17-26.		0
75	Imaging as a potential outcome measure in gout studies: A systematic literature review. Seminars in Arthritis and Rheumatism, 2016, 45, 570-579.	3.4	19
76	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. Journal of Rheumatology, 2016, 43, 150-153.	2.0	25
77	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	5.6	393
78	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. Journal of Rheumatology, 2015, 42, 2460-2464.	2.0	39
79	Outcome Measures for Gout Clinical Trials: a Summary of Progress. Current Treatment Options in Rheumatology, 2015, 1, 156-166.	1.4	7
80	Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout. Arthritis Care and Research, 2015, 67, 1304-1315.	3.4	101
81	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.9	545
82	An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. Journal of Rheumatology, 2015, 42, 1702-1707.	2.0	79
83	Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20). Annals of the Rheumatic Diseases, 2015, 74, 2144-2150.	0.9	19
84	Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2015, 74, 1868-1874.	0.9	145
85	Outcome Measures in Acute Gout: A Systematic Literature Review. Journal of Rheumatology, 2014, 41, 558-568.	2.0	28
86	Survival, momentum, and things that make me "come" patients' perceptions of goal setting after stroke. Disability and Rehabilitation, 2014, 36, 1020-1026.	1.8	69
87	Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 574-580.	2.0	16
88	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 569-573.	2.0	26
89	Establishing a person-centred framework of self-identity after traumatic brain injury: a grounded theory study to inform measure development. BMJ Open, 2014, 4, e004630.	1.9	36
90	The experience of having psoriasis through the lens of the International Classification of Functioning, Disability and Health (ICF). Australasian Journal of Dermatology, 2014, 55, 241-249.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Complementary and Alternative Medicine Use in Patients With Gout. Journal of Clinical Rheumatology, 2014, 20, 16-20.	0.9	11
92	Concerns of Patients With Gout Are Incompletely Captured by OMERACT-Endorsed Domains of Measurement for Chronic Gout Studies. Journal of Clinical Rheumatology, 2014, 20, 138-140.	0.9	10
93	Self-Reflective Meaning Making in Troubled Times. Qualitative Health Research, 2014, 24, 1033-1047.	2.1	30
94	Toward Development of a Tophus Impact Questionnaire. Journal of Clinical Rheumatology, 2014, 20, 251-255.	0.9	25
95	Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2286-2289.	2.0	32
96	Classification Criteria: Peripheral Spondyloarthropathy and Psoriatic Arthritis. Current Rheumatology Reports, 2013, 15, 317.	4.7	26
97	New classification criteria for gout: a framework for progress. Rheumatology, 2013, 52, 1748-1753.	1.9	37
98	Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskeletal Disorders, 2013, 14, 363.	1.9	39
99	Measurement of outcome in gout. Indian Journal of Rheumatology, 2013, 8, S11-S15.	0.4	4
100	The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clinical Rheumatology, 2013, 32, 247-251.	2.2	39
101	A Delphi Exercise to Identify Characteristic Features of Gout “Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. Journal of Rheumatology, 2013, 40, 498-505.	2.0	25
102	Do Patient Preferences for Core Outcome Domains for Chronic Gout Studies Support the Validity of Composite Response Criteria?. Arthritis Care and Research, 2013, 65, 1259-1264.	3.4	21
103	Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset. Rheumatology, 2012, 51, 1820-1824.	1.9	25
104	The Work Instability Scale Predicts Absenteeism in People With Gout and Suggests a Higher Risk for Those in Manual Occupations. Journal of Clinical Rheumatology, 2012, 18, 405-410.	0.9	4
105	A pilot cluster randomized controlled trial of structured goal-setting following stroke. Clinical Rehabilitation, 2012, 26, 327-338.	2.2	17
106	National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology, 2012, 51, 901-909.	1.9	167
107	Nail Disease in Psoriatic Arthritis: Distal Phalangeal Bone Edema Detected by Magnetic Resonance Imaging Predicts Development of Onycholysis and Hyperkeratosis. Journal of Rheumatology, 2012, 39, 841-843.	2.0	28
108	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	3.4	598

#	ARTICLE	IF	CITATIONS
109	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	3.4	1,268
110	Clinical Features of Gout. , 2012, , 105-120.		2
111	Developing a provisional definition of flare in patients with established gout. Arthritis and Rheumatism, 2012, 64, 1508-1517.	6.7	90
112	Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis and Rheumatism, 2012, 64, 2529-2536.	6.7	230
113	Impact of Psoriatic Arthritis on the Patient: Through the Lens of the WHO International Classification of Functioning, Health, and Disability. Current Rheumatology Reports, 2012, 14, 369-374.	4.7	33
114	Diagnosis of Gout: Considering Clinical and Research Settings. Current Rheumatology Reviews, 2011, 7, 97-105.	0.8	4
115	Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers. Seminars in Arthritis and Rheumatism, 2011, 40, 483-500.	3.4	45
116	Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials. Journal of Rheumatology, 2011, 38, 1467-1470.	2.0	23
117	Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care and Research, 2011, 63, 1605-1612.	3.4	97
118	Gout measures: Gout Assessment Questionnaire (GAQ, GAQ2.0), and physical measurement of tophi. Arthritis Care and Research, 2011, 63, S59-63.	3.4	14
119	Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Annals of the Rheumatic Diseases, 2011, 70, 597-604.	0.9	81
120	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. Journal of Rheumatology, 2011, 38, 898-903.	2.0	101
121	Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study. Annals of the Rheumatic Diseases, 2011, 70, 1091-1094.	0.9	37
122	Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?. Journal of Rheumatology, 2011, 38, 1462-1466.	2.0	17
123	Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities. Journal of Rheumatology, 2011, 38, 1458-1461.	2.0	21
124	Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 589-604.	3.3	76
125	Effect of Psoriatic Arthritis According to the Affected Categories of the International Classification of Functioning, Disability and Health. Journal of Rheumatology, 2010, 37, 1885-1891.	2.0	33
126	The Patient Activity Scale-II Is a Generic Indicator of Active Disease in Patients with Rheumatic Disorders. Journal of Rheumatology, 2010, 37, 1932-1934.	2.0	11

#	ARTICLE	IF	CITATIONS
127	Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. <i>Arthritis Research and Therapy</i> , 2010, 12, R164.	3.5	87
128	Value for money “recasting the problem in terms of dynamic access prioritisation. <i>Disability and Rehabilitation</i> , 2010, 32, 1020-1027.	1.8	9
129	Outcome Domains for Studies of Acute and Chronic Gout. <i>Journal of Rheumatology</i> , 2009, 36, 2342-2345.	2.0	147
130	Progress in Measurement Instruments for Acute and Chronic Gout Studies. <i>Journal of Rheumatology</i> , 2009, 36, 2346-2355.	2.0	53
131	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. <i>Journal of Rheumatology</i> , 2009, 36, 1792-1799.	2.0	38
132	MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. <i>Arthritis Research and Therapy</i> , 2009, 11, R2.	3.5	48
133	A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 888-891.	0.9	65
134	Establishing outcome domains for evaluating treatment of acute and chronic gout. <i>Current Opinion in Rheumatology</i> , 2008, 20, 173-178.	4.3	3
135	Drug use and toxicity in psoriatic disease: focus on methotrexate. <i>Journal of Rheumatology</i> , 2008, 35, 1454-7.	2.0	30
136	Open-Label Extension Studies. <i>Pharmaceutical Medicine</i> , 2007, 21, 115-120.	0.4	3
137	Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. <i>Arthritis and Rheumatism</i> , 2007, 57, 487-494.	6.7	82
138	Using Rasch analysis to compare the psychometric properties of the Short Form 36 physical function score and the Health Assessment Questionnaire disability index in patients with psoriatic arthritis and rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 723-729.	6.7	65
139	Diagnostic Criteria of Psoriatic Arthritis. , 2007, , 19-28.		0
140	Outcome evaluations in gout. <i>Journal of Rheumatology</i> , 2007, 34, 1381-5.	2.0	28
141	Differential association of general and health self-efficacy with disability, health-related quality of life and psychological distress from musculoskeletal pain in a cross-sectional general adult population survey. <i>Pain</i> , 2006, 125, 225-232.	4.2	24
142	Effectiveness of a clinical pathway for acute stroke care in a district general hospital: an audit. <i>BMC Health Services Research</i> , 2006, 6, 16.	2.2	22
143	Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2665-2673.	6.7	2,811
144	Understanding psoriatic arthritis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2005, 66, 163-167.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Evidence for inpatient rehabilitation as an effective intervention. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 200-204.	0.5	4
146	Musculoskeletal pain in the adult New Zealand population: prevalence and impact. New Zealand Medical Journal, 2005, 118, U1629.	0.5	33
147	Outcome measures in psoriatic arthritis. Journal of Rheumatology, 2005, 32, 2262-9.	2.0	37
148	A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2004, 34, 575-584.	3.4	90
149	Development of diagnostic criteria for psoriatic arthritis: Methods and process. Current Rheumatology Reports, 2004, 6, 299-305.	4.7	20
150	Quality of life of people with rheumatoid arthritis as measured by the World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF): Score distributions and psychometric properties. Arthritis and Rheumatism, 2004, 51, 350-357.	6.7	75
151	Assessment of outcome in psoriatic arthritis. Current Opinion in Rheumatology, 2004, 16, 350-356.	4.3	16
152	Self-Valuation and Societal Valuations of Health State Differ With Disease Severity in Chronic and Disabling Conditions. Medical Care, 2004, 42, 1143-1151.	2.4	31
153	The burden of rheumatic disorders in general practice: consultation rates for rheumatic disease and the relationship to age, ethnicity, and small-area deprivation. New Zealand Medical Journal, 2004, 117, U1098.	0.5	16
154	Relationship Between Process and Outcome in Stroke Care. Stroke, 2003, 34, 713-717.	2.0	54
155	Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis. Journal of Rheumatology, 2003, 30, 2645-58.	2.0	37
156	Epidemiology of psoriatic arthritis. Current Opinion in Rheumatology, 2002, 14, 98-103.	4.3	43
157	Case definition of psoriatic arthritis. Lancet, The, 2000, 356, 2095.	13.7	19